CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed
Drug / intervention
rosiglitazone(drug), blood pressure lowering effectdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00290394
NCT00290394Phase 4Completed
CompareCT.gov

Study of PPAR Gamma Agonist-Rosiglitazone in Normotensive Type 2 Diabetics With Ambulatory Blood Pressure Monitoring

Baskent University·interventional·Posted Feb 13, 2006·Updated Feb 13, 2006

In Brief

A Phase 4 clinical trial evaluating rosiglitazone(drug), blood pressure lowering effect for Diabetes Mellitus, Type 2. Completed, across 1 site.

Detailed Summary

The purpose of this study was to determine the effects of rosiglitazone in normotensive type 2 diabetic patients with regard to its blood-pressure-reducing effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesTurkey (Türkiye)
Collaborators--

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 13, 2006
Enrollment StartMar 1, 2004
Study CompletionAug 1, 2004
TodayJul 2, 2026
Posted 20.4 years ago

Interventions

rosiglitazone(drug), blood pressure lowering effectdrug